🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

642 results for “Lacuna Pharma Pty Ltd” Clear

  1. Busulfan Fresenius Kabi 6 mg/ml concentrate for solution for infusion, Neupogen 30 MU (0,6 mg/ml) solución inyectable en jeringa precargada filgrastim, Mozobil 20 mg/ml solution for injection, Merilen

    Lacuna Pharma Pty Ltd

    Inherited metabolic disorder of the enzyme pyruvate kinase which affects the survival of red blood cells, Pyruvate Kinase Deficiency

    phase 1 small molecule active

    1 trial

  2. Ceftobiprole OATP1B interaction study

    Lacuna Pharma Pty Ltd

    Community-acquired bacterial pneumonia

    phase 1 other active

    1 trial

  3. Clinical research trial for evaluating different properties, such as safety, tolerability and body interaction, of a new drug called ALY688ER, administered as subcutaneous injection in healthy overweight or obese people.

    Lacuna Pharma Pty Ltd

    NASH

    phase 1 other active

    1 trial

  4. Clinical study to evaluate the safety of investigational medicinal product called AD-O51.4 in patients with advanced malignancies

    Lacuna Pharma Pty Ltd

    Patients suffering from cancer without further treatment options.

    phase 1 other active

    1 trial

  5. Comparative Bioavailability of Cabozantinib Film-Coated Tablets in Healthy Participants Under Fasting Conditions

    Lacuna Pharma Pty Ltd

    No medical condition.

    phase 1 other active

    1 trial

  6. Comparative Bioavailability of Lisdexamfetamine Dimesylate 70 mg in Healthy Subjects Under Fasting Conditions

    Lacuna Pharma Pty Ltd

    No medical condition.

    phase 1 other active

    1 trial

  7. Comparative Bioavailability of Ruxolitinib 20 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions.

    Lacuna Pharma Pty Ltd

    No medical condition.

    phase 1 other active

    1 trial

  8. Creon 25.000, harde maagsapresistente capsules 25.000 eenheden, Creon 50000 Ph.Eur. lipase units, Creon 25000 Ph.Eur. lipase units, Creon 10000 Ph.Eur. lipase units, Creon 75000 Ph.Eur. lipase units, Creon® 10000 Capsules

    Lacuna Pharma Pty Ltd

    patients with cystic fibrosis suffering from pancreatic exocrine insufficiency

    phase 1 small molecule active

    1 trial

  9. DMT in healthy subjects

    Lacuna Pharma Pty Ltd

    Stroke

    phase 1 other active

    1 trial

  10. DOSE-FINDING CLINICAL TRIAL TO EVALUATE OF INTESTINAL LACTASE ACTIVITY VIA ORAL GAXILOSE ADMINISTRATION IN HEALTHY ADULT VOLUNTEERS

    Lacuna Pharma Pty Ltd

    Hypolactasia

    phase 1 other active

    1 trial

  11. Dose Escalation Study with Bispecific Antibodies in Adult Patients with Lupus Nephritis

    Lacuna Pharma Pty Ltd

    Lupus Nephritis

    phase 1 other active

    1 trial

  12. Double-Blind, Randomized, Placebo-Controlled, Phase 1b, Pharmacodynamic Trial of TEV-56192 Following a Single Intravenous Administration in Healthy Participants

    Lacuna Pharma Pty Ltd

    Pruritus

    phase 1 other active

    1 trial

  13. Evaluation of AG-181 in Subjects 18 to 69 Years of Age With Phenylketonuria

    Lacuna Pharma Pty Ltd

    Phenylketonuria

    phase 1 other active

    1 trial

  14. Evaluation of bioequivalence of two products containing 400 mg ibuprofen and 100 mg caffeine: Ibuprofen / Caffeine 400 mg / 100 mg coated granules (Test) vs. Thomapyrin TENSION DUO, 400mg / 100mg Filmtabletten (Reference). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy volunteers

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers.

    phase 1 other active

    1 trial

  15. Evaluation of bioequivalence of two products containing 50 mg dimenhydrinate: Dimenhydrinate 50 mg (Test) vs. Vomex A 50 mg Lösung zum Einnehmen im Beutel (Comparator). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy volunteers

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers.

    phase 1 other active

    1 trial

  16. Evaluation of bioequivalence of two products containing 600 mg ibuprofen: Ibuprofen Sopharma 600 mg film-coated tablets (Test) vs. Brufen 600 mg film-coated tablets (Comparator). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy volunteers

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers.

    phase 1 other active

    1 trial

  17. Evaluation of the bioavailability of two transdermal gel preparations containing 0.1% w/w estradiol under fasting conditions: Estradiol/INTERMED gel 0.1% w/w (Test) vs. ESTREVA® 0.1%, gel (Comparator). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy postmenopausal women

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers.

    phase 1 other active

    1 trial

  18. Evaluation of vamorolone CYP3A4 induction on midazolam (a sensitive CYP3A4 substrate) pharmacokinetics

    Lacuna Pharma Pty Ltd

    Phase I study in healthy male volunteers. Intended indication: Duchenne muscular dystrophy and Becker muscular dystrophy

    phase 1 other active

    1 trial

  19. First in human, Phase 1a/1b Study of KM-023 in healthy volunteers and Olmsted syndrome patients

    Lacuna Pharma Pty Ltd

    Olmsted syndrome

    phase 1 other active

    1 trial

  20. First-in-Human Study of ALN-SNCA in Adult Participants with Early Parkinson’s Disease (PD)

    Lacuna Pharma Pty Ltd

    Parkinson's disease

    phase 1 other active

    1 trial

  21. First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants with Atopic Dermatitis

    Lacuna Pharma Pty Ltd

    Atopic Dermatits

    phase 1 other active

    1 trial

  22. First-in-human Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of the Adjuvanted Universal Influenza Vaccine “fH1/DSP-0546LP” in Healthy Adults

    Lacuna Pharma Pty Ltd

    Influenza

    phase 1 other active

    1 trial

  23. INZ-701, INZ-701

    Lacuna Pharma Pty Ltd

    Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency or ATP-binding Cassette Sub-family C Member 6 (ABCC6) Deficiency

    phase 1 small molecule active

    1 trial

  24. Intralesional Cemiplimab for Adult Patients with Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

    Lacuna Pharma Pty Ltd

    Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources